Synairgen plc (LON:SNG) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $12.73 and traded as low as $9.00. Synairgen shares last traded at $9.00, with a volume of 3,352 shares changing hands.
Separately, FinnCap reissued a “corporate” rating on shares of Synairgen in a research report on Wednesday, July 24th.
The company has a market cap of $10.12 million and a PE ratio of -2.64. The business has a 50-day simple moving average of GBX 10.26 and a 200-day simple moving average of GBX 12.69.
Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; IFN-ß that is in Phase-I clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold; and LOXL2 inhibitor, which is in Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Read More: Capital gains and your 401(k) or IRA
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.